Theodoros Kelesidis

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6445465/publications.pdf

Version: 2024-02-01

153 papers 6,253 citations

36 h-index 75 g-index

162 all docs 162 docs citations

times ranked

162

9660 citing authors

#	Article	IF	CITATIONS
1	Adipokines, Weight Gain and Metabolic and Inflammatory Markers After Antiretroviral Therapy Initiation: AIDS Clinical Trials Group (ACTG) A5260s. Clinical Infectious Diseases, 2022, 74, 857-864.	2.9	7
2	Instigators of COVID-19 in Immune Cells Are Increased in Tobacco Cigarette Smokers and Electronic Cigarette Vapers Compared With Nonsmokers. Nicotine and Tobacco Research, 2022, 24, 413-415.	1.4	6
3	ApoA-I mimetics reduce systemic and gut inflammation in chronic treated HIV. PLoS Pathogens, 2022, 18, e1010160.	2.1	10
4	Race and sex differences in HDL peroxide content among American adults with and without type 2 diabetes. Lipids in Health and Disease, 2022, 21, 18.	1.2	9
5	OUP accepted manuscript. European Journal of Preventive Cardiology, 2022, , .	0.8	O
6	Expression of Key Inflammatory Proteins Is Increased in Immune Cells From Tobacco Cigarette Smokers But Not Electronic Cigarette Vapers: Implications for Atherosclerosis. Journal of the American Heart Association, 2021, 10, e019324.	1.6	11
7	The ApoA-I mimetic peptide 4F attenuates in vitro replication of SARS-CoV-2, associated apoptosis, oxidative stress and inflammation in epithelial cells. Virulence, 2021, 12, 2214-2227.	1.8	9
8	Update in Viral Infections in the Intensive Care Unit. Frontiers in Medicine, 2021, 8, 575580.	1.2	14
9	Association of 1 Vaping Session With Cellular Oxidative Stress in Otherwise Healthy Young People With No History of Smoking or Vaping. JAMA Pediatrics, 2021, 175, 1174.	3.3	8
10	Advanced Glycation End Products Associated With Cardiometabolic Biomarkers In Treated HIV Infection. Open Forum Infectious Diseases, 2021, 8, ofab423.	0.4	1
11	Increased Expression of Proatherogenic Proteins in Immune Cell Subtypes in Tobacco Cigarette Smokers But Not in Electronic Cigarette Vapers. Canadian Journal of Cardiology, 2021, 37, 1175-1180.	0.8	4
12	Electronic and Tobacco Cigarettes Alter Polyunsaturated Fatty Acids and Oxidative Biomarkers. Circulation Research, 2021, 129, 514-526.	2.0	9
13	Short Communication: Plasma Lymphocyte Activation Gene 3 and Subclinical Coronary Artery Disease in the Multicenter AIDS Cohort Study. AIDS Research and Human Retroviruses, 2021, 37, 842-845.	0.5	1
14	ApoA-I mimetics favorably impact cyclooxygenase 2 and bioactive lipids that may contribute to cardiometabolic syndrome in chronic treated HIV. Metabolism: Clinical and Experimental, 2021, 124, 154888.	1.5	2
15	Apolipoprotein A-I mimetics attenuate macrophage activation in chronic treated HIV. Aids, 2021, 35, 543-553.	1.0	8
16	Sudden Cardiac Arrest in a Patient With Myxedema Coma and COVID-19. Journal of the Endocrine Society, 2020, 4, bvaa130.	0.1	22
17	Elevated Cellular Oxidative Stress in Circulating Immune Cells in Otherwise Healthy Young People Who Use Electronic Cigarettes in a Crossâ€Sectional Single enter Study: Implications for Future Cardiovascular Risk. Journal of the American Heart Association, 2020, 9, e016983.	1.6	21
18	Human T lymphotropic virus type 1 and risk of cardiovascular disease: Highâ€density lipoprotein dysfunction versus serum HDL concentrations. BioFactors, 2019, 45, 374-380.	2.6	4

#	Article	IF	CITATIONS
19	The impact of aerobic and isometric exercise on different measures of dysfunctional high-density lipoprotein in patients with hypertension. European Journal of Preventive Cardiology, 2019, 26, 1301-1309.	0.8	16
20	Highâ€density lipoprotein lipid peroxidation as a molecular signature of the risk for developing cardiovascular disease: Results from MASHAD cohort. Journal of Cellular Physiology, 2019, 234, 16168-16177.	2.0	10
21	Lorcaserin treatment decreases body weight and reduces cardiometabolic risk factors in obese adults: A sixâ€month, randomized, placeboâ€controlled, doubleâ€blind clinical trial. Diabetes, Obesity and Metabolism, 2019, 21, 1487-1492.	2.2	38
22	Greater IL-6, D-dimer, and ICAM-1 Levels Are Associated With Lower Small HDL Particle Concentration in the Multicenter AIDS Cohort Study. Open Forum Infectious Diseases, 2019, 6, ofz474.	0.4	4
23	Neisseria gonorrhoeae as a Rare Cause of Preseptal Cellulitis. Sexually Transmitted Diseases, 2019, 46, 813-815.	0.8	1
24	A Flow Cytometric Method to Determine Transfection Efficiency. Bio-protocol, 2019, 9, .	0.2	2
25	Low Levels of Endothelial Progenitor Cells and Their Association with Systemic Inflammation and Monocyte Activation in Older HIV-Infected Men. AIDS Research and Human Retroviruses, 2018, 34, 39-45.	0.5	9
26	Brief Report: Changes in Plasma RANKL-Osteoprotegerin in a Prospective, Randomized Clinical Trial of Initial Antiviral Therapy: A5260s. Journal of Acquired Immune Deficiency Syndromes (1999), 2018, 78, 362-366.	0.9	3
27	The Role of Lipoproteins in Mycoplasma-Mediated Immunomodulation. Frontiers in Microbiology, 2018, 9, 1682.	1.5	44
28	Soluble levels of receptor for advanced glycation endproducts and dysfunctional high-density lipoprotein in persons infected with human immunodeficiency virus. Medicine (United States), 2018, 97, e10955.	0.4	1
29	Dysfunctional High-Density Lipoprotein in Relation to Oxidative Stress and Human Immunodeficiency Virus., 2018,, 29-36.		0
30	Changes in Plasma Levels of Oxidized Lipoproteins and Lipoprotein Subfractions with Atazanavir-, Raltegravir-, Darunavir-Based Initial Antiviral Therapy and Associations with Common Carotid Artery Intima-Media Thickness: ACTG 5260s. Antiviral Therapy, 2017, 22, 113-126.	0.6	11
31	Assessment of Telomere Length, Phenotype, and DNA Content. Current Protocols in Cytometry, 2017, 79, 7.26.1-7.26.23.	3.7	3
32	Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein. Journal of Visualized Experiments, 2017, , .	0.2	7
33	Dysfunctional high-density lipoprotein from HIV+ individuals promotes monocyte-derived foam cell formation in vitro. Aids, 2017, 31, 2331-2336.	1.0	14
34	Detection of Donor-Derived Microparticles in the Peripheral Blood of a Hand Transplant Recipient During Rejection. Transplantation Direct, 2017, 3, e131.	0.8	4
35	<i>Rhodococcus</i> Infection in Solid Organ and Hematopoietic Stem Cell Transplant Recipients1. Emerging Infectious Diseases, 2017, 23, 510-512.	2.0	21
36	Spirochetal Lipoproteins and Immune Evasion. Frontiers in Immunology, 2017, 8, 364.	2.2	15

#	Article	IF	CITATIONS
37	î³H2Ax Expression as a Potential Biomarker Differentiating between Low and High Grade Cervical Squamous Intraepithelial Lesions (SIL) and High Risk HPV Related SIL. PLoS ONE, 2017, 12, e0170626.	1.1	1
38	A novel rapid and reproducible flow cytometric method for optimization of transfection efficiency in cells. PLoS ONE, 2017, 12, e0182941.	1.1	14
39	Predictors of Impaired HDL Function in HIV-1 Infected Compared to Uninfected Individuals. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 75, 354-363.	0.9	13
40	Endothelial Progenitor Cell Production Is Suppressed and Associated With Systemic Inflammation and Monocyte Activation in Older Human Immunodeficiency Virus (HIV)-Infected Men. Open Forum Infectious Diseases, 2016, 3, .	0.4	0
41	Changes in Markers of T-Cell Senescence and Exhaustion With Atazanavir-, Raltegravir-, and Darunavir-Based Initial Antiviral Therapy: ACTG 5260s. Journal of Infectious Diseases, 2016, 214, 748-752.	1.9	9
42	Soluble Levels of Receptor for Advanced Glycation Endproducts (RAGE) and Progression of Atherosclerosis in Individuals Infected with Human Immunodeficiency Virus: ACTG NWCS 332. Inflammation, 2016, 39, 1354-1362.	1.7	5
43	Indications and Types of Antibiotic Agents Used in 6 Acute Care Hospitals, 2009–2010: A Pragmatic Retrospective Observational Study. Infection Control and Hospital Epidemiology, 2016, 37, 70-79.	1.0	37
44	Telmisartan increases vascular reparative capacity in older HIV-infected adults: a pilot study. HIV Clinical Trials, 2016, 17, 225-232.	2.0	5
45	Changes in Insulin Resistance After Initiation of Raltegravir or Protease Inhibitors With Tenofovir-Emtricitabine: AIDS Clinical Trials Group A5260s. Open Forum Infectious Diseases, 2016, 3, ofw174.	0.4	38
46	Oxidized lipoproteins are associated with markers of inflammation and immune activation in HIV-1 infection. Aids, 2016, 30, 2625-2633.	1.0	35
47	Body Composition Changes After Initiation of Raltegravir or Protease Inhibitors: ACTG A5260s. Clinical Infectious Diseases, 2016, 62, 853-862.	2.9	137
48	The Zoonotic Potential of Daptomycin Nonâ€susceptible Enterococci. Zoonoses and Public Health, 2015, 62, 1-6.	0.9	2
49	Effects Of Strength Training On Haptoglobin. Medicine and Science in Sports and Exercise, 2015, 47, 468.	0.2	0
50	In Vitro Susceptibility of Gemella Species From Clinical Isolates. Open Forum Infectious Diseases, 2015, 2, .	0.4	7
51	First Report of Ventriculoperitoneal Shunt Infection due toCyberlindnera fabianii. Case Reports in Infectious Diseases, 2015, 2015, 1-6.	0.2	10
52	<i>In Vitro</i> Activity of Daptomycin in Combination with \hat{l}^2 -Lactams, Gentamicin, Rifampin, and Tigecycline against Daptomycin-Nonsusceptible Enterococci. Antimicrobial Agents and Chemotherapy, 2015, 59, 4279-4288.	1.4	39
53	Telmisartan to reduce cardiovascular risk in older HIV-infected adults: a pilot study. HIV Clinical Trials, 2015, 16, 197-206.	2.0	9
54	Changes in Inflammation and Immune Activation With Atazanavir-, Raltegravir-, Darunavir-Based Initial Antiviral Therapy: ACTG 5260s. Clinical Infectious Diseases, 2015, 61, 651-660.	2.9	103

#	Article	IF	CITATIONS
55	Substandard/Counterfeit Antimicrobial Drugs. Clinical Microbiology Reviews, 2015, 28, 443-464.	5.7	145
56	The safety of polymyxin antibiotics. Expert Opinion on Drug Safety, 2015, 14, 1687-1701.	1.0	85
57	Changes in Bone Mineral Density After Initiation of Antiretroviral Treatment With Tenofovir Disoproxil Fumarate/Emtricitabine Plus Atazanavir/Ritonavir, Darunavir/Ritonavir, or Raltegravir. Journal of Infectious Diseases, 2015, 212, 1241-1249.	1.9	100
58	Origin ofde novodaptomycin non susceptible enterococci. World Journal of Clinical Infectious Diseases, 2015, 5, 30.	0.5	0
59	Oxidized HDL Is Associated With Biomarkers of Inflammation and Immune Activation in Untreated and Treated HIV Infection. Open Forum Infectious Diseases, 2015, 2, .	0.4	0
60	Infections Following Total Artificial Heart Placement. Open Forum Infectious Diseases, 2015, 2, .	0.4	0
61	Dysfunctional HDL in HIV-Infected Adults With Suppressed Viremia on Antiretroviral Therapy May Directly Increase mRNA Expression Of CXCL16 and Sialoadhesin in Monocytes. Open Forum Infectious Diseases, 2015, 2, .	0.4	0
62	The Role of Platelet-Activating Factor in Chronic Inflammation, Immune Activation, and Comorbidities Associated with HIV Infection. AIDS Reviews, 2015, 17, 191-201.	0.5	29
63	A High Throughput Biochemical Fluorometric Method for Measuring Lipid Peroxidation in HDL. PLoS ONE, 2014, 9, e111716.	1.1	24
64	1327Factors associated with optimizing empiric antibiotic therapy in six hospitals. Open Forum Infectious Diseases, 2014, 1, S53-S54.	0.4	0
65	1613Dysfunctional HDL in HIV-infected adults with suppressed viremia on antiretroviral therapy may directly increase dendritic cell maturation and contribute to immune activation. Open Forum Infectious Diseases, 2014, 1, S430-S430.	0.4	0
66	How to approach and treat viral infections in ICU patients. BMC Infectious Diseases, 2014, 14, 321.	1.3	25
67	Immunomodulation of Antiretroviral Drug-Suppressed Chronic HIV-1 Infection in an Oral Probiotic Double-Blind Placebo-Controlled Trial. AIDS Research and Human Retroviruses, 2014, 30, 988-995.	0.5	56
68	The Interplay between Daptomycin and the Immune System. Frontiers in Immunology, 2014, 5, 52.	2.2	23
69	Mechanisms of Linezolid Resistance among Coagulase-Negative Staphylococci Determined by Whole-Genome Sequencing. MBio, 2014, 5, e00894-14.	1.8	35
70	Frequency of Susceptibility Testing for Patients with Persistent Methicillin-Resistant Staphylococcus aureus Bacteremia. Journal of Clinical Microbiology, 2014, 52, 357-361.	1.8	8
71	The Cross-Talk between Spirochetal Lipoproteins and Immunity. Frontiers in Immunology, 2014, 5, 310.	2.2	18
72	Assessment of empirical antibiotic therapy optimisation in six hospitals: an observational cohort study. Lancet Infectious Diseases, The, 2014, 14, 1220-1227.	4.6	104

#	Article	IF	Citations
73	Dyslipidemia and Cardiovascular Risk in Human Immunodeficiency Virus Infection. Endocrinology and Metabolism Clinics of North America, 2014, 43, 665-684.	1.2	35
74	Hdl Redox Activity is Increased in HIV-Infected Men in Association with Macrophage Activation and Non-Calcified Coronary Atherosclerotic Plaque. Antiviral Therapy, 2014, 19, 805-811.	0.6	16
75	Proximity to animal or crop operations may be associated with de novo daptomycin-non-susceptible Enterococcus infection. Epidemiology and Infection, 2014, 142, 221-224.	1.0	7
76	477In vitro Synergy Testing of Daptomycin with Beta-lactams, Gentamicin, Rifampin and Tigecycline against Daptomycin Non-Susceptible Enterococci. Open Forum Infectious Diseases, 2014, 1, S177-S178.	0.4	0
77	Role of RANKL-RANK/osteoprotegerin pathway in cardiovascular and bone disease associated with HIV infection. AIDS Reviews, 2014, 16, 123-33.	0.5	8
78	Dysfunctional HDL and progression of atherosclerosis in HIV-1-infected and -uninfected adults. Lipids in Health and Disease, 2013, 12, 23.	1.2	19
79	The emerging problem of linezolid-resistant <i>Staphylococcus</i> . Journal of Antimicrobial Chemotherapy, 2013, 68, 4-11.	1.3	288
80	Emergence of daptomycin-non-susceptible enterococci urinary tract isolates. Journal of Medical Microbiology, 2013, 62, 1103-1105.	0.7	4
81	Evolution of high-level daptomycin resistance in Enterococcus faecium during daptomycin therapy is associated with limited mutations in the bacterial genome. Journal of Antimicrobial Chemotherapy, 2013, 68, 1926-1928.	1.3	33
82	Perturbations of Circulating Levels of RANKL-Osteoprotegerin Axis in Relation to Lipids and Progression of Atherosclerosis in HIV-Infected and -Uninfected Adults: ACTG NWCS 332/A5078 Study. AIDS Research and Human Retroviruses, 2013, 29, 938-948.	0.5	13
83	Untrained young men have dysfunctional HDL compared with strength-trained men irrespective of body weight status. Journal of Applied Physiology, 2013, 115, 1043-1049.	1.2	13
84	Transport of daptomycin resistance genes between animals and humans as a possible mechanism for development of <i>development of <i <i="" develo<="" development="" of="" td=""><td>1.0</td><td>5</td></i></i></i></i></i></i></i></i></i></i>	1.0	5
85	Biomarkers of Microbial Translocation and Macrophage Activation: Association With Progression of Subclinical Atherosclerosis in HIV-1 Infection. Journal of Infectious Diseases, 2012, 206, 1558-1567.	1.9	178
86	Case-Control Study ComparingDe Novoand Daptomycin-Exposed Daptomycin-Nonsusceptible Enterococcus Infections. Antimicrobial Agents and Chemotherapy, 2012, 56, 2150-2152.	1.4	20
87	Genotypic and Phenotypic Evaluation of the Evolution of High-Level Daptomycin Nonsusceptibility in Vancomycin-Resistant Enterococcus faecium. Antimicrobial Agents and Chemotherapy, 2012, 56, 6051-6053.	1.4	55
88	Comment on: Successful therapy of treatment-emergent, non-clonal daptomycin-non-susceptible Enterococcus faecium infections. Journal of Antimicrobial Chemotherapy, 2012, 67, 515-516.	1.3	3
89	Extraparenchymal Neurocysticercosis in the United States. American Journal of the Medical Sciences, 2012, 344, 79-82.	0.4	24
90	Efficacy and safety of the probiotic <i>Saccharomyces boulardii</i> for the prevention and therapy of gastrointestinal disorders. Therapeutic Advances in Gastroenterology, 2012, 5, 111-125.	1.4	248

#	Article	IF	CITATIONS
91	An Unusual Cutaneous Tumor: African Histoplasmosis following Mudbaths: Case Report and Review. American Journal of Tropical Medicine and Hygiene, 2012, 86, 261-263.	0.6	19
92	Successful treatment of azole-resistant Candida spondylodiscitis with high-dose caspofungin monotherapy. Rheumatology International, 2012, 32, 2957-2958.	1.5	4
93	Effects of lipid-probe interactions in biochemical fluorometric methods that assess HDL redox activity. Lipids in Health and Disease, 2012, 11, 87.	1.2	21
94	De Novo Daptomycin-Nonsusceptible Enterococcal Infections. Emerging Infectious Diseases, 2012, 18, 674-676.	2.0	35
95	Epstein–Barr virusâ€associated hemophagocytic lymphohistiocytosis in Los Angeles County. Journal of Medical Virology, 2012, 84, 777-785.	2.5	17
96	Statins as Antiviral and Anti-inflammatory Therapy in HIV Infection. , 2012, 01, .		1
97	Is Isolation of Human Herpesvirus 6 in Kidney Transplant Recipients Clinically Significant?. Journal of Transplantation Technologies & Research, 2012, 02, .	0.1	0
98	Gastrointestinal symptoms among ambulatory HIV patients: appropriate symptom management requires improved symptom recognition. Annals of Gastroenterology, 2012, 25, 186-187.	0.4	0
99	Establishing Diagnosis of Haemophilus Parainfluenzae as Etiology of Culture-negative Endocarditis Using DNA Sequence Analysis on Tissue Specimen. American Journal of Medicine, 2011, 124, e9-e10.	0.6	12
100	Combination therapy with daptomycin, linezolid, and rifampin as treatment option for MRSA meningitis and bacteremia. Diagnostic Microbiology and Infectious Disease, 2011, 71, 286-290.	0.8	46
101	Does rituximab increase the incidence of infectious complications? A narrative review. International Journal of Infectious Diseases, 2011, 15, e2-e16.	1.5	178
102	Safety and Efficacy of Daptomycin in the Treatment of Gram-Positive Pathogens. Clinical Medicine Insights Therapeutics, 2011, 3, CMT.S6122.	0.4	0
103	Hypopituitarism Caused by Neurocysticercosis. American Journal of the Medical Sciences, 2011, 341, 414-416.	0.4	9
104	Preexposure Prophylaxis for HIV Prevention. Current HIV/AIDS Reports, 2011, 8, 94-103.	1.1	45
105	HIV-1 infected patients with suppressed plasma viremia on treatment have pro-inflammatory HDL. Lipids in Health and Disease, 2011, 10, 35.	1.2	25
106	Extraparenchymal neurocysticercosis in the United States: a case report. Journal of Medical Case Reports, 2011, 5, 359.	0.4	10
107	<i>Clostridium sphenoides</i> Bloodstream Infection in Man. Emerging Infectious Diseases, 2011, 17, 156-158.	2.0	4
108	A biochemical fluorometric method for assessing the oxidative properties of HDL. Journal of Lipid Research, 2011, 52, 2341-2351.	2.0	70

#	Article	IF	Citations
109	Human Papillomavirus (HPV) Detection Using In Situ Hybridization in Histologic Samples. American Journal of Clinical Pathology, 2011, 136, 119-127.	0.4	38
110	Daptomycin Nonsusceptible Enterococci: An Emerging Challenge for Clinicians. Clinical Infectious Diseases, 2011, 52, 228-234.	2.9	130
111	Multiple Intraventricular Neurocysticercal Cysts Treated with Endoscopy without Antiparasitic Therapy. American Journal of Tropical Medicine and Hygiene, 2011, 85, 1-2.	0.6	7
112	Bloodstream Infection with Anaerobiospirillum succiniciproducens: A Potentially Lethal Infection. Southern Medical Journal, 2011, 104, 205-214.	0.3	17
113	Giant Inguinoscrotal Hernia As a Cause of Hydronephrosis. American Journal of the Medical Sciences, 2010, 339, 174.	0.4	0
114	Smooth muscle tumour of the right groin: description of a unique case. Irish Journal of Medical Science, 2010, 179, 603-604.	0.8	0
115	Anaphylactoid reaction considered ciprofloxacin related: A case report and literature review. Clinical Therapeutics, 2010, 32, 515-526.	1.1	30
116	Maternal diet and cord blood leptin and adiponectin concentrations at birth. Clinical Nutrition, 2010, 29, 622-626.	2.3	24
117	Good's syndrome remains a mystery after 55Âyears: A systematic review of the scientific evidence. Clinical Immunology, 2010, 135, 347-363.	1.4	209
118	Interleukin-2-unresponsive immune defects in good syndrome: Letter to the Editor. Clinical Immunology, 2010, 135, 496-498.	1.4	3
119	Listeria endocarditis in a patient with psoriatic arthritis on infliximab: Are biologic agents as treatment for inflammatory arthritis increasing the incidence of Listeria infections?. Journal of Infection, 2010, 60, 386-396.	1.7	26
120	First Report of Treatment of <i>Anaerobiospirillum s</i> Infection with Levofloxacin. Journal of Clinical Microbiology, 2010, 48, 1970-1973.	1.8	17
121	Tracheobronchitis Caused by Methicillin-Resistant <i>Staphylococcus aureus</i> as a Cause of Chronic Wheezing in a Non-Ventilated Adult Patient with Tracheobronchomalacia. Respiration, 2010, 80, 148-156.	1.2	4
122	Giant right atrium with severe pulmonary hypertension. Cmaj, 2010, 182, E147-E147.	0.9	3
123	Successful treatment of pan-resistant Klebsiella pneumoniae pneumonia and bacteraemia with a combination of high-dose tigecycline and colistin. Journal of Medical Microbiology, 2010, 59, 1383-1386.	0.7	52
124	Quinolone-induced Hypoglycemia: A Life-threatening but Potentially Reversible Side Effect. American Journal of Medicine, 2010, 123, e5-e6.	0.6	21
125	Cytomegalovirus pseudotumor of the duodenum in a patient with AIDS: an unrecognized and potentially treatable clinical entity. International Journal of Infectious Diseases, 2010, 14, e274-e282.	1.5	29
126	Staphylococcus intermedius is not only a zoonotic pathogen, but may also cause skin abscesses in humans after exposure to saliva. International Journal of Infectious Diseases, 2010, 14, e838-e841.	1.5	30

#	Article	IF	CITATIONS
127	Acquired hemophilia as the cause of life-threatening hemorrhage in a 94-year-old man: a case report. Journal of Medical Case Reports, 2010, 4, 231.	0.4	8
128	An unusual foreign body as cause of chronic sinusitis: a case report. Journal of Medical Case Reports, 2010, 4, 157.	0.4	10
129	Candida albicans prosthetic hip infection in elderly patients: Is fluconazole monotherapy an option?. Scandinavian Journal of Infectious Diseases, 2010, 42, 12-21.	1.5	32
130	Emphysematous Cystitis in the Absence of Known Risk Factors: An Unusual Clinical Entity. Southern Medical Journal, 2009, 102, 942-946.	0.3	9
131	Postirradiation Klebsiella pneumoniae-Associated Necrotizing Fasciitis in the Western Hemisphere: A Rare but Life-Threatening Clinical Entity. American Journal of the Medical Sciences, 2009, 338, 217-224.	0.4	14
132	Unexplained high fever in an elderly patient treated with clonidine, duloxetine, and atorvastatin. Clinical Therapeutics, 2009, 31, 2894-2899.	1.1	9
133	Cord Blood Leptin and Adiponectin as Predictors of Adiposity in Children at 3 Years of Age: A Prospective Cohort Study. Pediatrics, 2009, 123, 682-689.	1.0	215
134	Levofloxacin-induced Hypoglycemia: A Rare but Life-threatening Side Effect of a Widely Used Antibiotic. American Journal of Medicine, 2009, 122, e3-e4.	0.6	24
135	Perineurioma of Esophagus: A First Case Report. American Journal of the Medical Sciences, 2009, 338, 230-232.	0.4	9
136	Human infections associated with wild birds. Journal of Infection, 2008, 56, 83-98.	1.7	145
137	Axillary Abscess in a Patient with Yersinia enterocolitica Infection as a Result of Exposure to Pork. American Journal of Medicine, 2008, 121, e1.	0.6	7
138	Tigecycline for the treatment of multidrug-resistant (including carbapenem-resistant) Acinetobacter infections: a review of the scientific evidence. Journal of Antimicrobial Chemotherapy, 2008, 62, 45-55.	1.3	170
139	Tigecycline for the treatment of multidrug-resistant Enterobacteriaceae: a systematic review of the evidence from microbiological and clinical studies. Journal of Antimicrobial Chemotherapy, 2008, 62, 895-904.	1.3	153
140	Isolation and Characterization of a Novel <i>Francisella</i> sp. from Human Cerebrospinal Fluid and Blood. Journal of Clinical Microbiology, 2008, 46, 2428-2431.	1.8	40
141	Leptin Does Not Mediate Short-Term Fasting-Induced Changes in Growth Hormone Pulsatility but Increases IGF-I in Leptin Deficiency States. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 2819-2827.	1.8	65
142	Regulation of adiponectin and its receptors in response to development of diet-induced obesity in mice. American Journal of Physiology - Endocrinology and Metabolism, 2007, 292, E1079-E1086.	1.8	127
143	Total and High-Molecular Weight Adiponectin in Relation to Metabolic Variables at Baseline and in Response to an Exercise Treatment Program: Comparative evaluation of three assays. Diabetes Care, 2007, 30, 280-285.	4.3	113
144	Growth hormone-binding protein is directly and IGFBP-3 is inversely associated with risk of female breast cancer. European Journal of Endocrinology, 2007, 156, 187-194.	1.9	15

#	Article	IF	CITATIONS
145	Counterfeit or substandard antimicrobial drugs: a review of the scientific evidence. Journal of Antimicrobial Chemotherapy, 2007, 60, 214-236.	1.3	187
146	Total and High-Molecular-Weight Adiponectin in Breast Cancer:In Vitroandin VivoStudies. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 1041-1048.	1.8	207
147	Plasma Adiponectin Concentrations and Risk of Incident Breast Cancer. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 1510-1516.	1.8	248
148	Community-acquired Acinetobacter infections. European Journal of Clinical Microbiology and Infectious Diseases, 2007, 26, 857-868.	1.3	137
149	Mycoplasma pneumoniae-associated myelitis: a comprehensive review. European Journal of Neurology, 2006, 13, 112-124.	1.7	79
150	Adiponectin and cancer: a systematic review. British Journal of Cancer, 2006, 94, 1221-1225.	2.9	429
151	Peptide YY levels are decreased by fasting and elevated following caloric intake but are not regulated by leptin. Diabetologia, 2006, 49, 169-173.	2.9	60
152	The HAART-Induced Metabolic Syndrome. , 2006, , 403-426.		1
153	Central nervous system manifestations of Mycoplasma pneumoniae infections. Journal of Infection, 2005, 51, 343-354.	1.7	162